Table 5.

The difference of overall survival in cancer patients with high PODXL expression vs low/median expression

Cancer type	No. of cancer tissues			P value
	High	Low/Median	Total
ACC	20	59	79	0.37
BLCA	102	304	406	0.34
BRCA	272	809	1081	0.4
CESC	73	218	291	0.77
CHOL	9	27	36	0.57
COAD	69	210	279	0.32
ESCA	46	138	184	0.16
GBM	39	113	152	0.041
HNSCC	130	389	519	0.3
KICH	15	49	64	0.35
KIRC	134	397	531	< 0.0001
KIRP	72	215	287	0.0037
LAML	43	120	163	0.64
LIHC	93	272	365	0.82
LUAD	125	377	502	0.37
LUSC	126	368	494	0.33
DLBC	12	35	47	0.21
MESO	22	63	85	0.23
OVSC	76	227	303	0.95
PAAD	45	132	177	0.013
PCPG	45	134	179	0.13
PRAD	125	372	497	0.92
READ	42	123	165	0.44
SARC	65	194	259	0.12
SKCM	115	344	459	0.22
TGCT	34	100	134	0.29
THYM	30	89	119	0.78
THCA	127	377	504	0.87
UCS	15	41	56	0.58
UCEC	136	407	543	0.006
UVM	20	60	80	0.36

ACC adrenocortical carcinoma, BLCA bladder urothelial carcinoma, BRCA breast invasion carcinoma, CESE cervical squamous cell carcinoma, CHOL cholangiocarcinoma, COAD colon adenocarcinoma, ESCA esophageal carcinoma, GBM glioblastoma multiforme, HNSCC head and neck squamous cell carcinoma, KICH kidney chromophobe, KIRC kidney renal clear cell carcinoma, KIRP kidney renal papillary cell carcinoma, LAML acute myeloid leukemia, LIHC liver hepatocellular carcinoma, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, DLBC lymphoid neoplasm diffuse large B-cell lymphoma, MESO mesothelioma, OVSC ovarian serous cystadenocarcinoma, PAAD pancreatic adenocarcinoma, PCPG pheochromocytoma and paraganglioma, PRAD prostate adenocarcinoma, READ rectum adenocarcinoma, SARC sarcoma, SKCM skin cutaneous melanoma, STAD stomach adenocarcinoma, TGCT testicular germ cell tumors, THYM thymoma, THCA thyroid carcinoma, UCS uterine carcinosarcoma, UCEC uterine corpus endometrial carcinoma, UVM uveal melanoma